| For: | Patoulias DI, Boulmpou A, Teperikidis E, Katsimardou A, Siskos F, Doumas M, Papadopoulos CE, Vassilikos V. Cardiovascular efficacy and safety of dipeptidyl peptidase-4 inhibitors: A meta-analysis of cardiovascular outcome trials. World J Cardiol 2021; 13(10): 585-592 [PMID: 34754403 DOI: 10.4330/wjc.v13.i10.585] |
|---|---|
| URL: | https://www.wjgnet.com/1949-8462/full/v13/i10/585.htm |
| Number | Citing Articles |
| 1 |
Kevin Yau, Joel G. Ray, Nivethika Jeyakumar, Bin Luo, Sheikh Abdullah, Stephanie N. Dixon, Sara Wing, Kristin K. Clemens, Fabio Castrillon-Ramirez, Jacob A. Udell, Alejandro Meraz-Munoz, Ann Young, Ziv Harel, Jeffrey Perl, Lawrence A. Leiter, Amit X. Garg, David Z.I. Cherney, Ron Wald. Glucagon-like Peptide-1 Receptor Agonists and Risk of Major Adverse Cardiovascular Events in Patients With CKD. American Journal of Kidney Diseases 2026; 87(2) doi: 10.1053/j.ajkd.2025.09.010
|
| 2 |
Jelena Dimnjaković, Tamara Buble, Tamara Poljičanin, Hana Brborović, Emanuel Brađašević, Ognjen Brborović, Zubing Mei. Identifying high-risk combinations of metformin during COVID-19. PLOS One 2026; 21(3) doi: 10.1371/journal.pone.0343979
|
| 3 |
Mayra Alejandra Jaimes Campos, Iván Andújar, Felix Keller, Gert Mayer, Peter Rossing, Jan A. Staessen, Christian Delles, Joachim Beige, Griet Glorieux, Andrew L. Clark, William Mullen, Joost P. Schanstra, Antonia Vlahou, Kasper Rossing, Karlheinz Peter, Alberto Ortiz, Archie Campbell, Frederik Persson, Agnieszka Latosinska, Harald Mischak, Justyna Siwy, Joachim Jankowski. Prognosis and Personalized In Silico Prediction of Treatment Efficacy in Cardiovascular and Chronic Kidney Disease: A Proof-of-Concept Study. Pharmaceuticals 2023; 16(9) doi: 10.3390/ph16091298
|
| 4 |
Waqas Tahir, Hannah Beba, Gail Fortes-Mayer, Partha Kar, Nazish Khan, Nicola Milne, Jim Moore, Sharvanu Saha, Marc Atkin. Expert consensus on solutions to improve implementation of NICE type 2 diabetes guideline (NG28) by health systems in England: a Delphi panel by the INNOVATE-28 Working Group. BMJ Open 2025; 15(6) doi: 10.1136/bmjopen-2024-093955
|
| 5 |
Basavana Goudra, Geno J. Merli, Michael Green. Glucose-Lowering Agents Developed in the Last Two Decades and Their Perioperative Implications. Pharmaceuticals 2024; 18(1) doi: 10.3390/ph18010004
|
| 6 |
Anastasia Nikolaidou, Ioannis Ventoulis, Georgios Karakoulidis, Vasileios Anastasiou, Stylianos Daios, Spyridon-Filippos Papadopoulos, Matthaios Didagelos, John Parissis, Theodoros Karamitsos, Kalliopi Kotsa, Antonios Ziakas, Vasileios Kamperidis. Hypoglycemic Drugs in Patients with Diabetes Mellitus and Heart Failure: A Narrative Review. Medicina 2024; 60(6) doi: 10.3390/medicina60060912
|
| 7 |
Mangesh Tiwaskar, Chii-Min Hwu, Marcelo Lim, Apeksha Bhandary, Iris Chang. Treatment Preferences for Novel Type 2 Diabetes Oral Medications: Insights from the Asian Diabetes Patient Preference Study. Diabetes Therapy 2025; 16(9) doi: 10.1007/s13300-025-01770-3
|
| 8 |
Erin S LeBlanc, Neon Brooks, Melinda Davies, Ranee Chatterjee. Sex-Specific Cardiovascular Risk Factors and Treatment in Females With T2DM and CVD: Developments and Knowledge Gaps. The Journal of Clinical Endocrinology & Metabolism 2024; 109(12) doi: 10.1210/clinem/dgae655
|
| 9 |
Lin Luo, Changsen Zhu, Shaona Yang, Yuan Sun, Muyang Rong, Tianrong Li. Therapeutic advances in type 1 myotonic dystrophy complicated with type 2 diabetes mellitus. Frontiers in Neurology 2025; 16 doi: 10.3389/fneur.2025.1640563
|
| 10 |
Kathrine Kold Sørensen, Puriya Daniel Würtz Yazdanfard, Bochra Zareini, Ulrik Pedersen-Bjergaard, Vanja Kosjerina, Mikkel Porsborg Andersen, Anders Munch, Johan Sebastian Ohlendorff, Stefanie Schmid, Stefanie Lanzinger, Pratik Choudhary, Clare Gillies, Safoora Gharibzadeh, Marcus Lind, Viktor Tasselius, Jens Michelsen, Thomas Alexander Gerds, Christian Torp-Pedersen. Real-world cardiovascular effectiveness of sustained glucagon-like peptide 1 GLP-1 receptor agonist usage in type 2 diabetes. Cardiovascular Diabetology 2025; 24(1) doi: 10.1186/s12933-025-02915-1
|
| 11 |
Kevin Yau, Joel G. Ray, Nivethika Jeyakumar, Bin Luo, Sheikh Abdullah, Eric McArthur, Stephanie N. Dixon, Sara Wing, Kristin K. Clemens, Fabio Castrillon-Ramirez, Jacob A. Udell, Alejandro Meraz-Munoz, Ann Young, Ziv Harel, Jeffrey Perl, Vikas S. Sridhar, Huajing Ni, Tae Won Yi, Lawrence A. Leiter, Amit X. Garg, David Z.I. Cherney, Ron Wald. Glucagon-Like Peptide 1 Receptor Agonists and the Risk of Emergency Department Visits and Hospitalization in Patients With Chronic Kidney Disease. Diabetes Care 2025; 48(9) doi: 10.2337/dc24-2811
|
| 12 |
S. G. Kanorskii, Yu. S. Kovalenko. Features of development, the possibility of prevention and treatment of atrial fibrillation in patients with diabetes mellitus. South Russian Journal of Therapeutic Practice 2023; 4(1) doi: 10.21886/2712-8156-2023-4-1-19-27
|
| 13 |
Mar Garcia Zamora, Gemma García–Lluch, Lucrecia Moreno, Juan Pardo, Consuelo Cháfer Pericas. Assessment of sodium-glucose cotransporter 2 inhibitors (SGLT2i) and other antidiabetic agents in Alzheimer’s disease: A population-based study. Pharmacological Research 2024; 206 doi: 10.1016/j.phrs.2024.107295
|
| 14 |
Ofri Mosenzon, Alice YY Cheng, Alejandro A. Rabinstein, Simona Sacco. Diabetes and Stroke: What Are the Connections?. Journal of Stroke 2023; 25(1) doi: 10.5853/jos.2022.02306
|
| 15 |
Akash Fichadiya, Amity Quinn, Flora Au, Dennis Campbell, Darren Lau, Paul Ronksley, Reed Beall, David J T Campbell, Stephen B Wilton, Derek S Chew. Association between sodium–glucose cotransporter-2 inhibitors and arrhythmic outcomes in patients with diabetes and pre-existing atrial fibrillation. Europace 2024; 26(3) doi: 10.1093/europace/euae054
|
| 16 |
Praloy Chakraborty, Stanley Nattel, Kumaraswamy Nanthakumar, Kim A. Connelly, Mansoor Husain, Sunny S. Po, Andrew C.T. Ha. Sudden cardiac death due to ventricular arrhythmia in diabetes mellitus: A bench to bedside review. Heart Rhythm 2024; 21(10) doi: 10.1016/j.hrthm.2024.05.063
|
| 17 |
Devkumar Durgaprasad Tiwari, Ipseeta Ray Mohanty, Ujwala Maheswari, Prithviraj M. Erande, Vandana M Thorat, Aneesa B. Sayed. Myocardial-salvaging Effects of a Novel Polyherbal Combination with Dipeptidyl Peptidase-4 Inhibitory Activity. Nigerian Postgraduate Medical Journal 2025; 32(3) doi: 10.4103/npmj.npmj_103_25
|
| 18 |
A.B.M. Kamrul-Hasan, Deep Dutta, Lakshmi Nagendra, Meha Sharma, Shinjan Patra, Saptarshi Bhattacharya. Role of anagliptin, a dipeptidyl peptidase-4 inhibitor, in managing type 2 diabetes: A systematic review and meta-analysis. Medicine 2024; 103(28) doi: 10.1097/MD.0000000000038870
|
| 19 |
Jelena Dimnjaković, Tamara Buble, Ognjen Brborović. Observational studies on the association of outpatient antidiabetic medication use and COVID-19 outcomes: are the findings more relevant to diabetes management than to COVID-19 pathology? A mini-review. Frontiers in Clinical Diabetes and Healthcare 2026; 7 doi: 10.3389/fcdhc.2026.1760695
|
| 20 |
Chung-Han Ho, Yi-Chen Shao, Yu-Cih Wu, Kuang-Ming Liao. Dipeptidyl Peptidase-4 Inhibitor Use and Risk of Major Adverse Cardiovascular Events in Patients with COPD and Diabetes: A Nationwide Retrospective Cohort Study. International Journal of Chronic Obstructive Pulmonary Disease 2026; doi: 10.2147/COPD.S608033
|
| 21 |
Anoop Misra, Naveed Sattar, Amerta Ghosh, Mahmoud Nassar, Ranil Jayawardena, Ritesh Gupta. Type 2 diabetes in South Asians. BMJ 2025; 390 doi: 10.1136/bmj-2024-079801
|
| 22 |
R. R. Minsafin, E. N. Saykina, A.V. Kalmykov, M. L. Maksimov. Non-glycemic effects of dipeptidyl peptidase-4 inhibitors: efficacy and safety. Terapevt (General Physician) 2025; (10) doi: 10.33920/MED-12-2510-03
|
| 23 |
Suzan Khalil, William Hicks, Floyd W. Burke, Ishak A. Mansi. Association of Glucagon-Like Peptide-1 Receptor Agonist with Incident Atrial Fibrillation. American Journal of Cardiovascular Drugs 2025; 25(6) doi: 10.1007/s40256-025-00751-y
|
| 24 |
I‐Weng Yen, Hung‐Yuan Li. Dipeptidyl peptidase‐4 inhibition targeting vascular senescence as a novel treatment for atherosclerosis. Journal of Diabetes Investigation 2024; 15(2) doi: 10.1111/jdi.14100
|
| 25 |
Jessica Kearney, Luigi Gnudi. The Pillars for Renal Disease Treatment in Patients with Type 2 Diabetes. Pharmaceutics 2023; 15(5) doi: 10.3390/pharmaceutics15051343
|
| 26 |
Mihai Grigore, Andreea-Maria Grigore, Martin-Graur Ruxandra-Elena, Verde Ioana, Gabriela Uscoiu, Camelia Nicolae, Ana-Maria Balahura, Adriana-Mihaela Ilieșiu. Diabetes Mellitus and Atrial Fibrillation: Mechanistic Insights and Therapeutic Impacts of Glucose-Lowering Drugs. Life 2025; 16(1) doi: 10.3390/life16010016
|
| 27 |
Khawaja M. Talha, Gregg C. Fonarow, Salim S. Virani, Javed Butler. Glucocentric Drugs in Cardiovascular Disease Protection and Heart Failure. Methodist DeBakey Cardiovascular Journal 2022; 18(5) doi: 10.14797/mdcvj.1155
|
| 28 |
Binish A Ahmad, Isha M Sanghani, Rithika Sayabugari, Hannah Biju, Akshaya Siddegowda, Minnu Ittiachen Kinattingal, Sai Goutham Reddy Yartha, Prajyoth M Gaonkar, Syed Shireen Andrabi, Yogeshkumar K Vaghamashi, Arunika Korwar. Beyond Blood Sugar: Investigating the Cardiovascular Effects of Antidiabetic Drugs. Cureus 2023; doi: 10.7759/cureus.46373
|
| 29 |
David K Ryan, Ruth H Keogh, Elizabeth Williamson, R Thomas Lumbers, Karla Diaz-Ordaz, Anoop D Shah, Patrick Bidulka. Enhancing evidence-based care using trial emulation in electronic health records: real-world effects of empagliflozin in people with type 2 diabetes. BMJ Open Diabetes Research & Care 2026; 14(1) doi: 10.1136/bmjdrc-2025-005672
|
| 30 |
Yi-Hsin Chan, Tze-Fan Chao, Shao-Wei Chen, Hsin-Fu Lee, Pei-Ru Li, Wei-Min Chen, Yung-Hsin Yeh, Chi-Tai Kuo, Lai-Chu See, Gregory Y. H. Lip. The risk of incident atrial fibrillation in patients with type 2 diabetes treated with sodium glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, and dipeptidyl peptidase-4 inhibitors: a nationwide cohort study. Cardiovascular Diabetology 2022; 21(1) doi: 10.1186/s12933-022-01549-x
|
| 31 |
Talip E Eroglu, Ruben Coronel, Patrick C Souverein. Sodium-glucose cotransporter-2 inhibitors and the risk of atrial fibrillation in patients with type 2 diabetes: a population-based cohort study. European Heart Journal - Cardiovascular Pharmacotherapy 2024; 10(4) doi: 10.1093/ehjcvp/pvae022
|
| 32 |
Airi Matsuzaki, Kenji Momo, Ayako Watanabe, Hiromi Koshizuka, Yuka Kashiwabara, Katsumi Tanaka, Tadanori Sasaki. Risk Assessment for Heart Failure in Patients with Type 2 Diabetes Mellitus Treated with Dipeptidyl Peptidase 4 Inhibitor Using a Large Claims Dataset. Biological and Pharmaceutical Bulletin 2023; 46(9) doi: 10.1248/bpb.b23-00073
|
| 33 |
Pann Ei Hnynn Si, S. Parker, D. Abdelhafiz, A. Summerbell, S. Muzulu, Ahmed H. Abdelhafiz. Cardiovascular risk reduction in older people with type 2 diabetes mellitus-a comprehensive narrative review. Diabetes Research and Clinical Practice 2024; 211 doi: 10.1016/j.diabres.2024.111662
|
| 34 |
Pankaj Kumar Jha, Heta Shukla, Altaf Makwana, Ashutosh Kakkad. Type 2 Diabetes in 2024 - From Early Suspicion to Effective Management. 2023; doi: 10.5772/intechopen.1002309
|
| 35 |
Alfredo Caturano, Erica Vetrano, Raffaele Galiero, Celestino Sardu, Luca Rinaldi, Vincenzo Russo, Marcellino Monda, Raffaele Marfella, Ferdinando Carlo Sasso. Advances in the Insulin–Heart Axis: Current Therapies and Future Directions. International Journal of Molecular Sciences 2024; 25(18) doi: 10.3390/ijms251810173
|
| 36 |
Inês Henriques Vieira, Tânia Santos Carvalho, Joana Saraiva, Leonor Gomes, Isabel Paiva. Diabetes and Stroke: Impact of Novel Therapies for the Treatment of Type 2 Diabetes Mellitus. Biomedicines 2024; 12(5) doi: 10.3390/biomedicines12051102
|
| 37 |
Cristina-Elena Zbârcea, Cristian-Daniel Marineci, Andrei Văleanu, Cornel Chiriță, Oana-Cristina Șeremet. Drug–Drug and Drug–Disease Interactions Across Antidiabetic Drug Classes: A Narrative Review and Practical Recommendations. Diabetology 2026; 7(6) doi: 10.3390/diabetology7060108
|
| 38 |
Elina Khattab, Michaelia Kyriakou, Elena Leonidou, Stefanos Sokratous, Angeliki Mouzarou, Michael M. Myrianthefs, Nikolaos P. E. Kadoglou. Critical Appraisal of Pharmaceutical Therapy in Diabetic Cardiomyopathy—Challenges and Prospectives. Pharmaceuticals 2025; 18(1) doi: 10.3390/ph18010134
|
| 39 |
Zia Shariat-Madar, Fakhri Mahdi. Potential Molecular Biomarkers for Predicting and Monitoring Complications in Type 2 Diabetes Mellitus. Molecules 2025; 30(22) doi: 10.3390/molecules30224448
|
| 40 |
Shayan Khan, William Herbst, Farbod Zahedi Tajrishi, Sonali Notani, Alexander Knight, Zina Jamil, Keith C. Ferdinand. Integrating GLP-1 Receptor Agonists into Modern Stroke Prevention: Evidence, Mechanisms, and Clinical Consideration—A Narrative Review. Biomedicines 2026; 14(4) doi: 10.3390/biomedicines14040743
|
| 41 |
André J. Scheen. Clinical pharmacology of antidiabetic drugs: What can be expected of their use?. La Presse Médicale 2023; 52(1) doi: 10.1016/j.lpm.2022.104158
|
| 42 |
Angeliki Bourazana, Grigorios Giamouzis, John Skoularigis, Filippos Triposkiadis, Andrew Xanthopoulos. Glucose lowering does not necessarily reduce cardiovascular risk in type 2 diabetes. World Journal of Cardiology 2022; 14(4): 266-270 doi: 10.4330/wjc.v14.i4.266
|
| 43 |
Talip E. Eroglu, Ruben Coronel, Fredrik Folke, Gunnar Gislason. Glucagon-like peptide-1 receptor agonist use is associated with reduced risk of out-of-hospital cardiac arrest in women with type 2 diabetes: A nationwide nested case-control study. Resuscitation Plus 2024; 20 doi: 10.1016/j.resplu.2024.100821
|
| 44 |
André J. Scheen. Antidiabetic agents and risk of atrial fibrillation/flutter: A comparative critical analysis with a focus on differences between SGLT2 inhibitors and GLP-1 receptor agonists. Diabetes & Metabolism 2022; 48(6) doi: 10.1016/j.diabet.2022.101390
|
| 45 |
Kathrine Kold Sørensen, Puriya Daniel Würtz Yazdanfard, Bochra Zareini, Hannah Karin Wood‐Kurland, Ulrik Pedersen‐Bjergaard, Mikkel Porsborg Andersen, Jens Michelsen, Henrik Imberg, Marcus Lind, Sara Hallström, Stefanie Lanzinger, Anders Munch, Johan Sebastian Ohlendorff, Thomas Alexander Gerds, Christian Torp‐Pedersen. Sustained glucagon‐like peptide‐1 receptor agonist treatment improves glycemic control and reduces all‐cause mortality compared to dipeptidyl peptidase‐4 inhibitors: A real‐world target trial emulation in type 2 diabetes. Diabetes, Obesity and Metabolism 2026; 28(5) doi: 10.1111/dom.70581
|
| 46 |
Allie Seminer, Alfredi Mulihano, Clare O’Brien, Finn Krewer, Maria Costello, Conor Judge, Martin O’Donnell, Catriona Reddin. Cardioprotective Glucose-Lowering Agents and Dementia Risk. JAMA Neurology 2025; 82(5) doi: 10.1001/jamaneurol.2025.0360
|
| 47 |
Yosuke Nabeshima, Atsushi Tanaka, Koichi Node. Sweet relationship between SGLT2 inhibition and heart failure. International Journal of Cardiology 2024; 410 doi: 10.1016/j.ijcard.2024.132223
|
| 48 |
Monica Kanki, Morag J. Young. The mineralocorticoid receptor: a new chapter for therapeutic regulation of diabetic cardiomyopathy. Journal of Molecular and Cellular Cardiology 2026; 213 doi: 10.1016/j.yjmcc.2026.01.004
|
| 49 |
Konstantinos Grigoriou, Paschalis Karakasis, Konstantinos Pamporis, Panagiotis Theofilis, Dimitrios Patoulias, Efstratios Karagiannidis, Barbara Fyntanidou, Antonios P. Antoniadis, Nikolaos Fragakis. Atrial Fibrillation in Diabetes: Pathogenesis and Targeted Rhythm Control Strategies. Current Issues in Molecular Biology 2025; 47(7) doi: 10.3390/cimb47070559
|
| 50 |
Dwight D. Harris, Sharif A. Sabe, Mark Broadwin, Chris Stone, Krishna Bellam, Akshay Malhotra, M. Ruhul Abid, Frank W. Sellke, Meijing Wang. Dipeptidyl peptidase 4 inhibitor sitagliptin decreases myocardial fibrosis and modulates myocardial insulin signaling in a swine model of chronic myocardial ischemia. PLOS ONE 2024; 19(7) doi: 10.1371/journal.pone.0307922
|
| 51 |
Nina M. Radisavljevic, Slavica S. Mutavdzin Krneta, Dragan M. Djuric. Cardiovascular Toxicity. Advances in Biochemistry in Health and Disease 2025; 33 doi: 10.1007/978-3-031-90598-8_9
|
| 52 |
Shuyao Zhang, Fnu Sidra, Carlos A. Alvarez, Mustafa Kinaan, Ildiko Lingvay, Ishak A. Mansi. Healthcare utilization, mortality, and cardiovascular events following GLP1-RA initiation in chronic kidney disease. Nature Communications 2024; 15(1) doi: 10.1038/s41467-024-54009-3
|
| 53 |
Young Sang Lyu, Seok Oh, Jin Hwa Kim, Sang Yong Kim, Myung Ho Jeong. Comparison of SGLT2 inhibitors with DPP-4 inhibitors combined with metformin in patients with acute myocardial infarction and diabetes mellitus. Cardiovascular Diabetology 2023; 22(1) doi: 10.1186/s12933-023-01914-4
|
| 54 |
Patryk Graczyk, Aleksandra Dach, Kamil Dyrka, Andrzej Pawlik. Pathophysiology and Advances in the Therapy of Cardiomyopathy in Patients with Diabetes Mellitus. International Journal of Molecular Sciences 2024; 25(9) doi: 10.3390/ijms25095027
|
| 55 |
Ehsan Amini-Salehi, Maryam Hasanpour, Abdulhadi Alotaibi, Pegah Rashidian, Seyyed Mohammad Hashemi, Amir Nasrollahizadeh, Negin Letafatkar, Parsa Saberian, Reza Amani-Beni, Najmeh Shanbehzadeh. Global research trends on DPP-4 inhibitors and cardiovascular outcomes: a comprehensive bibliometric analysis. Annals of Medicine & Surgery 2025; 87(4) doi: 10.1097/MS9.0000000000003089
|
| 56 |
Yunwen Xu, Thomas A. Boyle, Beini Lyu, Shoshana H. Ballew, Elizabeth Selvin, Alexander R. Chang, Lesley A. Inker, Morgan E. Grams, Jung-Im Shin. Glucagon-like peptide-1 receptor agonists and the risk of atrial fibrillation in adults with diabetes: a real-world study. Journal of General Internal Medicine 2024; 39(7) doi: 10.1007/s11606-023-08589-3
|
| 57 |
Viet-Thi Tran, Raphaël Porcher, Elodie Perrodeau, Sally Yaacoub, Isabelle Boutron, Philippe Ravaud. Practical elements to consider when emulating a target trial. Journal of Clinical Epidemiology 2026; 194 doi: 10.1016/j.jclinepi.2026.112205
|
| 58 |
Fu-Chih Hsiao, Kun-Chi Yen, Tze-Fan Chao, Shao-Wei Chen, Yi-Hsin Chan, Pao-Hsien Chu. New-Onset Atrial Fibrillation in Patients With Type 2 Diabetes Treated With Novel Glucose-Lowering Therapies. The Journal of Clinical Endocrinology & Metabolism 2022; 107(9) doi: 10.1210/clinem/dgac402
|
| 59 |
Bharat K. Kantharia, Mohammadreza Tabary, Lingling Wu, Xinyu Wang, Bharat Narasimhan, Dominik Linz, Jordi Heijman, Xander H. T. Wehrens. Diabetes and Atrial Fibrillation: Insight From Basic to Translational Science Into the Mechanisms and Management. Journal of Cardiovascular Electrophysiology 2025; 36(10) doi: 10.1111/jce.16655
|
| 60 |
C. Siafarikas, G. Karamanakos, K. Makrilakis, A. Tsolakidis, K. Mathioudakis, S. Liatis. Prevalence and Incidence of Medication-Treated Diabetes and Pattern
of Glucose-Lowering Treatment During the COVID-19 Pandemic: Real-World Data from
the Electronic Greek Prescription Database. Experimental and Clinical Endocrinology & Diabetes 2024; 132(09) doi: 10.1055/a-2307-4631
|
| 61 |
Simona Sacco, Matteo Foschi, Raffaele Ornello, Federico De Santis, Riccardo Pofi, Michele Romoli. Prevention and treatment of ischaemic and haemorrhagic stroke in people with diabetes mellitus: a focus on glucose control and comorbidities. Diabetologia 2024; 67(7) doi: 10.1007/s00125-024-06146-z
|
| 62 |
Kevin Yau, Ayodele Odutayo, Satya Dash, David Z.I. Cherney. Biology and Clinical Use of Glucagon-Like Peptide-1 Receptor Agonists in Vascular Protection. Canadian Journal of Cardiology 2023; 39(12) doi: 10.1016/j.cjca.2023.07.007
|
| 63 |
Kazi Islam, Rahib Islam, Ivan Nguyen, Hassan Malik, Humza Pirzadah, Barsha Shrestha, Isabella B. Lentz, Sahar Shekoohi, Alan D. Kaye. Diabetes Mellitus and Associated Vascular Disease: Pathogenesis, Complications, and Evolving Treatments. Advances in Therapy 2025; 42(6) doi: 10.1007/s12325-025-03185-9
|
| 64 |
Dwight D. Harris, Sharif A. Sabe, Mark Broadwin, Krishna Bellam, Cynthia M. Xu, Janelle W. Li, M. Ruhul Abid, Frank W. Sellke. DPP‐4 inhibitor sitagliptin treatment results in altered myocardial metabolic proteome and oxidative phosphorylation in a swine model of chronic myocardial ischemia. Physiological Reports 2024; 12(5) doi: 10.14814/phy2.15976
|
| 65 |
Alfredo Mauriello, Adriana Correra, Riccardo Molinari, Gerardo Elia Del Vecchio, Viviana Tessitore, Antonello D’Andrea, Vincenzo Russo. Mitochondrial Dysfunction in Atrial Fibrillation: The Need for a Strong Pharmacological Approach. Biomedicines 2024; 12(12) doi: 10.3390/biomedicines12122720
|